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Background
CD-NP (Cenderitide) is the only chimeric natriuretic pep-
tide that acts on both the A and B natriuretic peptide
receptors (NPR). This differential mechanism of action
reduces the arterial vasodilating properties, while retaining
the cardiac unloading and aldosterone inhibiting actions
of the NPR-A receptor in addition to the direct anti-remo-
deling actions of the NPR-B receptor. Our objective is to
determine the effects of 3 weeks of sustained delivery of
CD-NP via a single subcutaneous (SQ) injection of a fully
biodegradable in-situ polymer precipitation delivery sys-
tem (Gel system) in a model of experimental myocardial
infarction (MI).
Materials and methods
The CD-NP Gel system consists of 0.45% percentage
weight/weight (w/w) CD-NP formulated with 40% Poly
(lactic-co-glycolic acid) in 39.55% w/w N-methyl-2-
pyrrolidinone and 20% w/w triacetin. Coronary (LAD)
ligation rat (Wistar Male, 250-300g) model of MI was
used: Treatment group (CD-NP Gel, n=10) and Vehicle
group (Gel only, n=8). CD-NP gel or gel alone was admi-
nistered via a single SQ injection with induction of MI.
The delivery efficacy of the CD-NP Gel system, cardiac
function and structure, and cGMP were assessed 3-weeks
post MI.
Results
Plasma and urinary evaluations demonstrated a significant
elevation for both CD-NP and the second messenger
cGMP in the treatment group at 3 weeks as compared to
vehicle group: plasma CD-NP 5,000 ± 505 pg/ml vs 120 ±
6.2 pg/ml; plasma cGMP 170 ± 21.4 pmol/ml vs 112 ±
8.0 pmol/ml respectively. This confirms the CD-NP gel
system’s efficacy and the biological activity of released
peptide. Both mean arterial blood pressure and ejection
fraction at 3-weeks were found to be significantly higher
in treated group as compared to vehicle group, thus
suggesting improvements in overall cardiac function.
Heart/body weight ratio in treated group was found to be
significantly lower as compared to vehicle group. Left
ventricular fibrosis and collagen deposition was also signi-
ficantly reduced in treated rats. (p<0.05 comparing Treat-
ment group vs Vehicle group for the above mentioned
parameters).
Conclusion
This study demonstrates the efficacy and feasibility of a
novel chronic peptide polymer gel delivery system for the
dual NPR-A/B chimeric peptide CD-NP. Specifically, a
one time SQ injection of CD-NP Gel resulted in 3 weeks
sustained delivery of the functional peptide with favorable
cGMP activating actions and improved cardiac remodeling
in this model of experiment MI. Further studies are
warranted to translate the current study to human MI.
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